announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using Medtronic InterStim® Therapy reduced incontinent episodes and increased quality ...

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...

Minze Health announced that it entered into a three-year agreement with Medtronic to commercialize its overactive bladder ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

Sacral neuromodulation, which is also called interstim, acts to provide a small amount of electrical stimulation to the nerves that run through the tailbone (sacrum) to the bladder. For reasons we do ...

Medtronic plc today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the InterStim™ portfolio’s recharge-free device – and it ...

Certain healthcare conditions often go unspoken, leading to silent struggles that affect the lives of many. Overactive bladder (OAB) and fecal incontinence (FI) are two such conditions, impacting ...

A new multicenter study shows use of Medtronic’s InterStim Therapy via sacral nerve stimulation reduced incontinent episodes and improved quality of life in most patients with chronic fecal ...

ZANESVILLE – Dr. Mitesh Parekh, a urogynecologist with Genesis Urogynecology, has been recognized by Medtronic, a medical device company, for outstanding contribution in positively impacting the lives ...

The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—but Medtronic and Axonics Modulation Technologies are still aiming for a photo finish. For ...